Inovio Pharmaceuticals says it has completed Phase II enrolment for a mid-to-late stage US trial of its COVID-19 vaccine candidate INO-4800, as reported in the Financial Post.
Last September, the FDA a put on hold the Phase III portion of the US study of INO-4800 as it sought more information on the device used to inject the vaccine.
Inovio said it was actively working to address FDA's concerns and plans to respond in May.
The company is also developing next-generation COVID-19 vaccine candidates that could be tailored to known and potentially unknown SARS-CoV-2 variants.
To read more NewsPoints articles, click here.